Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GERN Stock Forecast 2025-2026
$1.32
Current Price
$836.25M
Market Cap
Buy 4
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to GERN Price Targets
+280.2%
To High Target of $5.00
+204.2%
To Median Target of $4.00
-24.0%
To Low Target of $1.00
GERN Price Momentum
+11.9%
1 Week Change
+23.4%
1 Month Change
-66.4%
1 Year Change
-62.7%
Year-to-Date Change
-67.8%
From 52W High of $4.09
+26.4%
From 52W Low of $1.04
📊 TOP ANALYST CALLS
Did GERN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Geron is one of their latest high-conviction picks.
Latest GERN Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, GERN has a bullish consensus with a median price target of $4.00 (ranging from $1.00 to $5.00). The overall analyst rating is Buy (7.7/10). Currently trading at $1.32, the median forecast implies a 204.2% upside. This outlook is supported by 4 Buy, 1 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Gil Blum at Needham, projecting a 280.2% upside. Conversely, the most conservative target is provided by Corinne Jenkins at Goldman Sachs, suggesting a 24.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GERN Analyst Ratings
4
Buy
1
Hold
1
Sell
GERN Price Target Range
Low
$1.00
Average
$4.00
High
$5.00
Current: $1.32
Latest GERN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GERN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 5, 2025 | Needham | Gil Blum | Buy | Maintains | $4.00 |
| Jul 10, 2025 | Goldman Sachs | Corinne Jenkins | Sell | Reinstates | $1.00 |
| May 8, 2025 | Scotiabank | Greg Harrison | Sector Perform | Downgrade | $1.50 |
| Mar 12, 2025 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $N/A |
| Mar 12, 2025 | Needham | Gil Blum | Buy | Reiterates | $5.00 |
| Feb 27, 2025 | Needham | Gil Blum | Buy | Maintains | $5.00 |
| Feb 27, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $4.00 |
| Feb 27, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $4.00 |
| Feb 27, 2025 | Stifel | Stephen Willey | Buy | Maintains | $4.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Emily Bodnar | Neutral | Downgrade | $N/A |
| Feb 18, 2025 | B. Riley Securities | Kalpit Patel | Buy | Maintains | $3.50 |
| Jan 13, 2025 | Needham | Gil Blum | Buy | Maintains | $7.00 |
| Dec 13, 2024 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $9.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $8.00 |
| Nov 5, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Initiates | $8.00 |
| Oct 16, 2024 | Scotiabank | Greg Harrison | Sector Outperform | Initiates | $6.00 |
| Sep 9, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $7.00 |
| Aug 9, 2024 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
| Jul 26, 2024 | Needham | Gil Blum | Buy | Reiterates | $6.00 |
Geron Corporation (GERN) Competitors
The following stocks are similar to Geron based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Geron Corporation (GERN) Financial Data
Geron Corporation has a market capitalization of $836.25M with a P/E ratio of -4.9x. The company generates $183.40M in trailing twelve-month revenue with a -43.6% profit margin.
Revenue growth is +67.1% quarter-over-quarter, while maintaining an operating margin of -29.4% and return on equity of -29.6%.
Valuation Metrics
Market Cap
$836.25M
Enterprise Value
$577.63M
P/E Ratio
-4.9x
PEG Ratio
0.2x
Price/Sales
4.6x
Growth & Margins
Revenue Growth (YoY)
+67.1%
Gross Margin
+97.8%
Operating Margin
-29.4%
Net Margin
-43.6%
EPS Growth
+67.1%
Financial Health
Cash/Price Ratio
+45.3%
Current Ratio
6.0x
Debt/Equity
49.0x
ROE
-29.6%
ROA
-7.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Geron Corporation (GERN) Business Model
About Geron Corporation
What They Do
Develops innovative cancer therapeutics.
Business Model
Geron Corporation focuses on developing and commercializing therapeutics for cancer, primarily through its lead product, imetelstat, a telomerase inhibitor. The company generates revenue by advancing its drug candidates through clinical trials and obtaining regulatory approvals, ultimately leading to commercialization and sales of effective cancer treatments.
Additional Information
Geron is based in California and emphasizes its commitment to extensive clinical trials and regulatory engagement to ensure the safety and efficacy of its products. The company collaborates with academic institutions and industry partners to leverage cutting-edge research aimed at addressing significant unmet medical needs in the oncology space.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
229
CEO
Mr. Harout Semerjian
Country
United States
IPO Year
1996
Website
www.geron.comGeron Corporation (GERN) Latest News & Analysis
Latest News
Quick Summary
Geron Corporation (GERN) will host its Q3 2025 earnings call on November 5, 2025, at 8:00 AM EST, featuring key executives and analysts from various research divisions.
Why It Matters
Geron Corporation's earnings call provides insights into its financial performance and strategic direction, influencing investor confidence and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights
1 month ago
Quick Summary
Geron Corporation (Nasdaq: GERN) reported Q3 2025 financial results, highlighting RYTELO’s potential impact on lower-risk MDS treatment. The company aims to address unmet medical needs in blood cancer.
Why It Matters
Geron Corporation's Q3 results and updates on RYTELO highlight its potential to transform treatment for lower-risk MDS, which may influence market perception and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Geron (GERN) reported a quarterly loss of $0.03 per share, matching the Zacks Consensus Estimate, an improvement from a loss of $0.04 per share a year prior.
Why It Matters
Geron's loss per share matched expectations, indicating stability. The smaller year-over-year loss may suggest improved financial performance, potentially influencing investor confidence and stock movement.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Geron reported Q3'25 Rytelo revenues of $47.2M, down from $49M in Q2, with no demand increase. Leadership changes include COO Andrew Grethlein's departure and Ahmed ElNawawi as new CCO.
Why It Matters
Geron's declining Rytelo revenues and lack of demand growth raise concerns about its market position. Leadership changes may impact strategy execution, affecting investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Geron Corporation (Nasdaq: GERN) announced acceptance of five abstracts for the 67th ASH Annual Meeting in December 2025, showcasing new data on its blood cancer treatment, RYTELO (imetelstat).
Why It Matters
Geron Corporation's acceptance of multiple abstracts for the ASH Annual Meeting highlights its ongoing research progress and potential breakthroughs in blood cancer treatment, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Geron Corporation CEO Harout Semerjian will present at the Stifel 2025 Healthcare Conference on November 11 and the Evercore Healthcare Conference on December 2.
Why It Matters
Geron Corporation's CEO presenting at major healthcare conferences signals potential updates on pipeline developments or strategic plans, influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About GERN Stock
What is Geron Corporation's (GERN) stock forecast for 2026?
Based on our analysis of 18 Wall Street analysts, Geron Corporation (GERN) has a median price target of $4.00. The highest price target is $5.00 and the lowest is $1.00.
Is GERN stock a good investment in 2026?
According to current analyst ratings, GERN has 4 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $1.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GERN stock?
Wall Street analysts predict GERN stock could reach $4.00 in the next 12 months. This represents a 204.2% increase from the current price of $1.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Geron Corporation's business model?
Geron Corporation focuses on developing and commercializing therapeutics for cancer, primarily through its lead product, imetelstat, a telomerase inhibitor. The company generates revenue by advancing its drug candidates through clinical trials and obtaining regulatory approvals, ultimately leading to commercialization and sales of effective cancer treatments.
What is the highest forecasted price for GERN Geron Corporation?
The highest price target for GERN is $5.00 from Gil Blum at Needham, which represents a 280.2% increase from the current price of $1.32.
What is the lowest forecasted price for GERN Geron Corporation?
The lowest price target for GERN is $1.00 from Corinne Jenkins at Goldman Sachs, which represents a -24.0% decrease from the current price of $1.32.
What is the overall GERN consensus from analysts for Geron Corporation?
The overall analyst consensus for GERN is bullish. Out of 18 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $4.00.
How accurate are GERN stock price projections?
Stock price projections, including those for Geron Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 4:28 PM UTC